Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
EMERYVILLE, Calif., Feb. 27, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.
| Conference Call Details | |||||||
| Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |||||||
| Toll Free: | 800-239-9838 | ||||||
| International: | 323-794-2551 | ||||||
| Conference ID: | 5092266 | ||||||
| Webcast: | http://public.viavid.com/index.php?id=128365 | ||||||
| Replays, available through March 20: | |||||||
| Domestic: | 844-512-2921 | ||||||
| International: | 412-317-6671 | ||||||
| Replay PIN: | 5092266 | ||||||
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
